Clinical

OSLO, Norway, June 01, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has expanded the…

Treatment with BDC-1001 at the recommended Phase 2 dose (RP2D) resulted in 29% objective response rate in evaluable patients with HER2-positive tumors, in both monotherapy and in combination with nivolumab20 mg/kg dosed every other week…

– A presentation on 4-week weight loss data from CT-388, a once…

8 AL Amyloidosis patients…

8 AL Amyloidosis patients…

Study Presented at Heart Rhythm Society Supports Wound-Healing…

New OTL-203 proof-of-concept data demonstrate extensive metabolic…

NEW YORK, May 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (the…

Updated Clinical Data from the Ongoing Phase 1b Dose-Escalation…

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Editas…